Trial · NCT02958865
Outcomes36
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 36
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Total Mayo Score at Week 8 (Induction Period) | Week 8 | The intent-to-treat (ITT) analysis set which included all randomized participants who received at least 1 dose of investigational product or placebo. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Number of Participants With AEs, SAEs and Discontinuation Due to AEs (Chronic Period) | From Week 8 up to Week 32 | The safety analysis set was defined as those participants who received at least one dose of PF-06651600, PF-06700841, or placebo. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Laboratory Test Abnormalities (Chronic Period) | From Week 8 to Week 32 | The participants with at least one observation of the given laboratory test while on study treatment or during lag time. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Laboratory Test Abnormalities-hematology (Chronic Period) | From Week 8 to Week 32 | Number of Participants Analyzed: the participants who received at least one dose of PF-06651600, PF-06700841, or placebo. Number Analyzed: the participants with at least one observation of the given laboratory test while on study treatment or during lag time. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Abnormal Vital Signs Data (Chronic Period) | From Week 8 to Week 32 | The participants evaluated against the criteria during the chronic period. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Abnormal ECG Findings (Chronic Period) | Week 8 to Week 32 | The participants evaluated against the criteria during the chronic period. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Serious Infections (Chronic Period) | Week 8 to Week 32 | The participants who received at least one dose of PF-06651600, PF-06700841, or placebo. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Laboratory Test Abnormalities-clinical Chemistry (Chronic Period) | Week 8 to Week 32 | Number of Participants Analyzed: the participants who received at least one dose of PF-06651600, PF-06700841, or placebo. Number Analyzed: the participants with at least one observation of the given laboratory test while on study treatment or during lag time. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Laboratory Test Abnormalities-urinalysis (Chronic Period) | Week 8 to Week 32 | Number of Participants Analyzed: the participants who received at least one dose of PF-06651600, PF-06700841, or placebo. Number Analyzed: the participants with at least one observation of the given laboratory test while on study treatment or during lag time. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs (All-causalities) (Induction Period) | From Day 1 up to Week 8 | The participants who received at least one dose of PF-06651600, PF-06700841, or placebo. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Laboratory Test Abnormalities (Induction Period) | From Day 1 up to Week 8 | The participants with at least one observation of the given laboratory test while on study treatment or during lag time. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Laboratory Test Abnormalities-hematology (Induction Period) | From Day 1 up to Week 8 | Number of Participants Analyzed: the participants who received at least one dose of PF-06651600, PF-06700841, or placebo. Number Analyzed: the participants with at least one observation of the given laboratory test while on study treatment or during lag time. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Laboratory Test Abnormalities-clinical Chemistry (Induction Period) | From Day 1 up to Week 8 | Number of Participants Analyzed: the participants who received at least one dose of PF-06651600, PF-06700841, or placebo. Number Analyzed: the participants with at least one observation of the given laboratory test while on study treatment or during lag time. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Laboratory Test Abnormalities- Urinalysis (Induction Period) | From Day 1 up to Week 8 | Number of Participants Analyzed: the participants who received at least one dose of PF-06651600, PF-06700841, or placebo. Number Analyzed: the participants with at least one observation of the given laboratory test while on study treatment or during lag time. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Abnormal Vital Signs Data (Induction Period) | From screening to Week 8 | Number of participants evaluated against the criteria during the induction period. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Abnormal Electrocardiogram (ECG) Findings (Induction Period) | From screening to Week 8 | Number of Participants Analyzed: the participants who received at least one dose of PF-06651600, PF-06700841, or placebo. Number Analyzed: the participants evaluated at the specified time point. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Serious Infections (Induction Period) | From Day 1 up to Week 8 | The participants who received at least one dose of PF-06651600, PF-06700841, or placebo. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage of Participants Achieving Remission Based on Total Mayo Score at Week 8 (Induction Period) | Week 8 | The ITT analysis set which included all randomized participants who received at least 1 dose of investigational product or placebo. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Achieving Improvement in Endoscopic Appearance Based on Total Mayo Score at Week 8 (Induction Period) | Week 8 | The ITT analysis set which included all randomized participants who received at least 1 dose of investigational product or placebo. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Achieving Clinical Response Based on Total Mayo Score at Week 8 (Induction Period) | Week 8 | The ITT analysis set which included all randomized participants who received at least 1 dose of investigational product or placebo. | Percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02958865/outcomes